“…
When treating parasitic diseases, IVM proved to be more effective than albendazole (RR 1,79; IC 95%: 1,55 to 2,08), but similar to thiabendazole (RR 0,80; 95% IC: 0,59 a 1,09); however, the adverse events were fewer using IVM ( Henriquez-Camacho et al, 2016 ). Systematic reviews with meta-analysis: Henriquez-Camacho et al, 2016 | Myiasis | Oral administration with a single dose of 250 μg/kg | Observational studies: Calvopina et al, 2020 |
Larva migrans | Oral administration of a daily single dose of 200 μg/kg for two days | Observational studies: Gerbig and Kempf, 2020 |
Pediculus humanus capitis | Oral dose of 400 μg/kg on the first and eighth day, or 200 μg/kg with a repeated dose after 10 days | Systematic review with meta-analysis: Jones and English 3rd., 2003 Randomized clinical trial: Chosidow et al, 2010 |
Rosacea (due to mite infestations, Demodex folliculorum) | Topical 1% IVM demonstrated that ivermectin can control papulopustular rosacea and improve life quality. | Systematic review and meta-analysis: Husein-ElAhmed and Steinhoff, 2020 |
Malaria | There exists evidence of reduction in malaria indexes and sporozoites by 77% when mass IVM is used ( Alout et al, 2014 ). |
…”